Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Bone Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533753

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533753

Psoriatic Arthritis Therapeutics

PUBLISHED:
PAGES: 276 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Psoriatic Arthritis Therapeutics Market to Reach US$20.5 Billion by 2030

The global market for Psoriatic Arthritis Therapeutics estimated at US$10.6 Billion in the year 2023, is expected to reach US$20.5 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2023-2030. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 16.7% CAGR

The Psoriatic Arthritis Therapeutics market in the U.S. is estimated at US$2.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 16.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Psoriatic Arthritis Therapeutics Market - Key Trends and Drivers Summarized

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects both the skin and joints, intertwining the symptoms of psoriasis with those of arthritis. This autoimmune disorder manifests in various forms, ranging from mild to severe, with symptoms including joint pain, stiffness, and swelling, along with the characteristic red, scaly patches of psoriasis. The management of PsA requires a comprehensive therapeutic approach that addresses both skin and joint symptoms to prevent joint damage and improve quality of life. The primary goal of PsA therapeutics is to reduce inflammation, control symptoms, and inhibit disease progression. Treatment regimens often begin with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to manage pain and inflammation, moving on to disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, when initial treatments are insufficient.

In recent years, significant advancements in the understanding of PsA's pathophysiology have led to the development of biologic therapies, which target specific components of the immune system that drive the disease. Tumor necrosis factor (TNF) inhibitors, such as adalimumab and etanercept, were among the first biologics approved for PsA treatment and have shown substantial efficacy in reducing joint and skin symptoms. More recently, interleukin (IL) inhibitors that target IL-17 and IL-23, such as secukinumab and ustekinumab, have been introduced, offering alternative mechanisms of action for patients who do not respond to TNF inhibitors. Additionally, small molecule inhibitors like Janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) inhibitors provide oral therapeutic options that are effective in controlling PsA symptoms. These therapies have transformed the treatment landscape of PsA, providing more personalized and effective options for patients.

The growth in the psoriatic arthritis therapeutics market is driven by several factors, including the increasing prevalence of the disease and a heightened awareness and diagnosis rate among healthcare professionals. Advancements in biotechnology and pharmaceutical research have led to the development of new and more effective treatments, expanding the range of therapeutic options available. The rising demand for biologics and targeted therapies, driven by their efficacy and relatively favorable side effect profiles, significantly contributes to market growth. Moreover, patient behavior is shifting towards seeking more advanced and specialized treatments, supported by greater access to healthcare information and improved healthcare infrastructure globally. Economic factors, such as increased healthcare expenditure and insurance coverage for chronic diseases, further support market expansion. Additionally, ongoing clinical trials and research into novel therapeutic targets promise to introduce new and improved treatments, ensuring sustained growth and innovation in the psoriatic arthritis therapeutics market. These factors collectively foster an environment where continuous advancements are made, aiming to enhance patient outcomes and quality of life for those suffering from PsA.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc
  • Aclaris Therapeutics, Inc.
  • Amgen, Inc.
  • Bristol-Myers Squibb Co
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Fresenius Kabi USA
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • SANOFI
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.;
Show more
Product Code: MCP26808

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Psoriatic Arthritis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Incidence of Psoriasis and Psoriatic Arthritis Propels Therapeutic Demand
    • Expansion of Treatment Indications for Existing Therapeutics
    • Regulatory Support for Faster Drug Approval Processes in Autoimmune Disorders to Encourage New Drug Development
    • Wider Adoption of Telemedicine in Chronic Disease Management Bodes Well for Growth
    • A Review of the Economic Burden of Psoriatic Arthritis and Impact on Healthcare Systems
    • Improved Healthcare Access Worldwide Influence Treatment Adoption & Demand
    • Market Impact of Biosimilars and Generic Anti-inflammatory Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Psoriatic Arthritis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Psoriatic Arthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Psoriatic Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • JAPAN
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CHINA
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • EUROPE
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Psoriatic Arthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Psoriatic Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • FRANCE
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • GERMANY
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Psoriatic Arthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Psoriatic Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • INDIA
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Psoriatic Arthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Psoriatic Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Psoriatic Arthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Psoriatic Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AFRICA
    • Psoriatic Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Psoriatic Arthritis Therapeutics by Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Psoriatic Arthritis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Psoriatic Arthritis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Psoriatic Arthritis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!